ZYBERNO
Stock Report
Updated Sep 1, 2026

JUPITER NEUROSCIENCES, INC. (JUNS)

Healthcare • NASDAQ

$3.38

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
JUPITER NEUROSCIENCES, INC. (JUNS) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-335.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

JUPITER NEUROSCIENCES, INC. (JUNS) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.38
Market Cap:$1.88M

Valuation Multiples (2)

P/S Ratio:86.46x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.49M

Price Action & Momentum (1)

% of 52-Week High:2.4%
B. Profitability Assessment

Return Metrics (4)

ROA:-232.8%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:-45,016.4%

Yield Metrics (2)

Earnings Yield:-$81.49
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.66x
Quick Ratio:0.62x
Cash Ratio:0.39x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-32.64x
Times Interest Earned:-32.64

Capital Structure (4)

Working Capital:-1,330,692.00
Cash And Cash Equivalents:1,521,874.00
Long Term Debt:$205.07K
Net Debt:-$398.56K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$21.80K
Cost Of Revenue Ttm:$4.23K

Profitability Breakdown (2)

$17.57K-$9.81M

Bottom Line Performance (3)

-$9.20M
Income Before Tax:$0.00
Ebitda Ttm:-9,811,783.00

Operating Expenses (5)

Operating Expenses:9,864,702.00
R And D Expense:1,871,783.00
Sga Expense:7,992,919.00
Income Tax Expense:$0.00
Interest Expense:272,918.00

Expense Ratios (3)

R And D To Revenue Percentage:7,720.3%
Sga To Revenue Percentage:32,967.3%
Ebitda Margin:-45,016.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.72M
Current Assets:$2.55M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:4,084,566.00
Current Liabilities:3,879,498.00
Long Term Debt:$205.07K
Short Term Debt:$918.24K

Equity & Capital (3)

Equity:-$365.97K
Retained Earnings:-$39.00M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:10,241.00
Inventory:135,290.00
Accounts Payable:918,243.00

Special Items (2)

Contract Liabilities:859.00
Stock Based Compensation:500,992.00
C. Cash Flow Analysis

Operating Activities (2)

-$5.78M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$5.51K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:150,000.00
Long Term Debt Issuance:$4.00M
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.27
-$4.27
Earnings Per Share Ttm:-$16.50

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.04
Operating Cash Flow Per Share:-$9.71

Book Value & Capital (2)

Book Value Per Share:-$0.66
Cash Per Share:2.73

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:2.13x
Days Sales Outstanding Ttm:171.50

Inventory Management (2)

Inventory Turnover Ttm:0.03x
Days Inventory Outstanding Ttm:11,671.20

Payables & Cash Cycle (2)

Days Payable Outstanding:79,215.01
Cash Conversion Cycle:-67,372.31
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:JUNS
Company Name:JUPITER NEUROSCIENCES, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:557.57K
Shares Outstanding Basic:557.57K
Shares Outstanding Diluted:557.57K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 15:35:22 UTC
Data Timestamp:2026-08-21T16:46:36.931504
Scroll to Top